Cidara Therapeutics, Inc. Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc.

CDTX

주식 순위 #3183
Cidara Therapeutics, Inc. is a biotechnology company specializing in the... Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
주가
$221.38
마지막 동기화: 2026-01-08
시가총액
$5.61B
변동 (1일)
0.00%
변동 (1년)
118.07%
국가
US
거래 Cidara Therapeutics, Inc. (CDTX)

카테고리

Healthcare
Cidara Therapeutics, Inc. (CDTX)의 EPS
September 2025 기준 EPS TTM: $-11.78
Cidara Therapeutics, Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $-11.78입니다. 2023년 말에는 회사의 EPS가 $-5.25였으며, 이는 2022년의 EPS $-9.61와 감소입니다.
Cidara Therapeutics, Inc.의 EPS 기록 (2012 ~ 2026)
매년 말의 EPS
연도 EPS 변화
2026 (TTM) $-11.78 -55.96%
2024 $-26.75 409.52%
2023 $-5.25 -45.37%
2022 $-9.61 -40.68%
2021 $-16.20 -55.04%
2020 $-36.03 34.54%
2019 $-26.78 -41.30%
2018 $-45.62 -28.37%
2017 $-63.69 -4.21%
2016 $-66.49 42.19%
2015 $-46.76 -83.88%
2014 $-290.15 249.41%
2013 $-83.04 85.77%
2012 $-44.70 0.00%
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
$17.32 -247.03%
US
$-7.98 -32.26%
US
$-5.29 -55.09%
AU
- -
CH
$27.74 -335.48%
NL